Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fostemsavir - ViiV Healthcare

Drug Profile

Fostemsavir - ViiV Healthcare

Alternative Names: BMS 626529 prodrug; BMS-663068; BMS-663068-03; Fostemsavir extended-release; Fostemsavir trometamol; Fostemsavir tromethamine; GSK 3684934; GSK-3684934A; HIV attachment inhibitor - ViiV Healthcare; Rukobia; Temsavir prodrug

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; ViiV Healthcare
  • Class 2 ring heterocyclic compounds; Antiretrovirals; Phosphoric acid esters; Piperazines; Pyridines; Pyrroles; Small molecules; Triazoles
  • Mechanism of Action Virus attachment inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 29 Jul 2022 Updated efficacy data and adverse events data from a phase III BRIGHTE trial in HIV-1 infections released by ViiV Healthcare
  • 02 Feb 2022 Launched for HIV-1 infections (Treatment-experienced) in USA, United Kingdom (PO)
  • 11 Aug 2021 Phase-I/II clinical trials in HIV-1 infections (Combination therapy, In adults, In adolescents, Treatment-experienced) in Spain (PO) in August 2021 (EudraCT2020-001029-30)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top